Рак

Medical researchers at University of Calgary reviewing glioblastoma scans alongside niacin supplements for a clinical trial illustration.

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

22 июня 2026 Сообщено ИИ Изображение, созданное ИИ Проверено фактами

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

FDA-approved drug shows promise against rare liver cancer

25 июня 2026 Сообщено ИИ

A study has identified how an existing medication could improve immunotherapy outcomes for fibrolamellar carcinoma. The rare liver cancer currently has no cure and often spreads before detection. Researchers demonstrated the approach using patient tumor samples.

Здоровье

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

Здоровье

Vaping after quitting smoking raises lung cancer death risk

Здоровье

Study identifies SLAMF6 as a self-activating brake on anti-cancer T cells, pointing to a new immunotherapy target

Home-based exercise program may ease “chemo brain” symptoms during chemotherapy, Phase II trial suggests

A Phase II randomized trial found that a six-week, home-based walking and resistance program improved attention test performance and reduced reports that others noticed cognitive problems among patients receiving chemotherapy. Low-dose ibuprofen improved some attention measures but showed mixed results on memory outcomes. The study was published in Cancer.